Skip to main content
This presentation gives a thorough description of the CAR T-cell therapy process for B-cell acute lymphoblastic leukemia (B-cell ALL), and discusses short- and long-term side effects and toxicities, expected outcomes, and ongoing research related to this therapy.
This presentation discusses CAR T-cell therapy for multiple myeloma. It explains what CAR T-cell therapy is, the process, and what clinical trials are indicating in regards to short- and long-term side effects, patient outcomes, and quality of life.
CAR T cell therapy has become an increasingly common treatment for patients with diffuse large B-cell lymphoma, (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma. This presentation discusses how it works, who is a good candidates for CAR T-cell therapy, and the risks and benefits of the treatment.
CAR T-cell therapy is a type of specialized immunotherapy that uses the patient's own modified T-cells to fight cancer. It is approved to treat certain blood cancers like lymphoma, leukemia, and multiple myeloma.
La terapia de células CAR T es un tratamiento nuevo para pacientes que tienen ciertos tipos de linfoma no Hodgkin. Conozca lo que implica someterse a una terapia de células CAR T, quién es un buen candidato y los posibles resultados.
Multiple studies have shown that most patients who receive chimeric antigen receptor (CAR) T-cell therapy report a good quality of life long-term. Learn how CAR T-cell therapy is performed and its short-term and long-term effects on patients and caregivers. Discover key differences between CAR T-cell, stem cell transplant and other and chemotherapy treatments.
Advanced age has traditionally been seen as prohibitive for treatments like stem cell transplants and CAR T therapy. This presentation reviews evidence that overall fitness is a crucial factor in reducing non-relapse mortality and that otherwise healthy elderly patients can have successful outcomes after transplant and CAR T-cell therapy.
CAR T therapy (chimeric antigen receptor therapy) is a new treatment strategy that has been shown to improve patient outcomes. In this lecture, Dr. William reviews the steps involved, including T-cell collection, lymphodepleting chemotherapy, reinfusion of T-cells, and follow-up care. Potential side effects and their treatments are discussed as wel
La terapia de Células CAR-T es una nueva terapia para pacientes con mieloma múltiple. Esta presentación explica qué es la terapia de Células CAR-T, cuál es su eficacia para los pacientes con mieloma y los posibles efectos secundarios.
CAR T-cell therapy is an exciting second-line option for patients living with relapsed multiple myeloma. In this presentation, Dr. Ahmed reviews each step in the CAR T process and discusses a number of studies that support its use. Potential side effects are reviewed, and exciting future trends are discussed.